ImmunoPrecise Antibodies Ltd. Files 6-K
Ticker: HYFT · Form: 6-K · Filed: Jun 10, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K on June 10, 2024, likely with a press release attached. Check for news.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 10, 2024, to report a press release dated June 10, 2024. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates ImmunoPrecise Antibodies Ltd. is providing updated information to the SEC, which could contain material news for investors.
Risk Assessment
Risk Level: low — This is a routine filing to submit a press release, with no immediate indication of significant financial changes or negative events.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Chief Financial Officer
- June 10, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by ImmunoPrecise Antibodies Ltd. to report a press release dated June 10, 2024.
Who signed this filing on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor, Chief Financial Officer, signed the filing on behalf of ImmunoPrecise Antibodies Ltd.
What is the filing date of this report?
The filing was made on June 10, 2024.
What exhibit is included with this filing?
Exhibit 99.1, a Press Release dated June 10, is included with this filing.
What is the principal executive office address for ImmunoPrecise Antibodies Ltd.?
The address of the principal executive offices is 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-10 14:23:10
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 11KB
- exhibit99-1x001.jpg (GRAPHIC) — 6KB
- 0001062993-24-012298.txt ( ) — 25KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: June 10, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Press Release dated June 10, 2024